Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Several in vitro and in vivo studies have reported the anti-inflammatory, anti-diabetic and anti-obesity effects of the flavonoid apigenin. However, the long-term supplementary effects of low-dose apigenin on obesity are unclear. Therefore, we investigated the protective effects of apigenin against obesity and related metabolic disturbances by exploring the metabolic and transcriptional responses in high-fat diet (HFD)-induced obese mice. C57BL/6J mice were fed an HFD or apigenin (0.005%, w/w)-supplemented HFD for 16 weeks. In HFD-fed mice, apigenin lowered plasma levels of free fatty acid, total cholesterol, apolipoprotein B and hepatic dysfunction markers and ameliorated hepatic steatosis and hepatomegaly, without altering food intake and adiposity. These effects were partly attributed to upregulated expression of genes regulating fatty acid oxidation, tricarboxylic acid cycle, oxidative phosphorylation, electron transport chain and cholesterol homeostasis, downregulated expression of lipolytic and lipogenic genes and decreased activities of enzymes responsible for triglyceride and cholesterol ester synthesis in the liver. Moreover, apigenin lowered plasma levels of pro-inflammatory mediators and fasting blood glucose. The anti-hyperglycemic effect of apigenin appeared to be related to decreased insulin resistance, hyperinsulinemia and hepatic gluconeogenic enzymes activities. Thus, apigenin can ameliorate HFD-induced comorbidities via metabolic and transcriptional modulations in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 2×
“Levels of plasma insulin and HOMA‐IR, a method used to quantify insulin resistance and β‐cell function [16], were also significantly decreased by apigenin (Figure 2B,C).”
MethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“IL-6 also plays a direct role in insulin resistance by inhibiting insulin receptor signal transduction and insulin action in hepatocytes [24].”
BackgroundBile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Surrogate markers of insulin resistance: A review
Singh, B. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i2.36 · Cited by 622 · cited 1×
“Insulin resistance and hyperinsulinemia are hallmarks of obesity and can induce many of the abnormalities associated with metabolic syndrome [17].”
BackgroundDissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.005 · Cited by 511 · cited 2×
“The hepatic overexpression of Dgat2, which catalyzes the final step of triglyceride synthesis, led to hepatic steatosis in mice [63], and liver-specific disruption of Pparγ or Srebf1 protected mice against hepatic steatosis [64].”
BackgroundNguyen, M. T. A., Satoh, H., Favelyukis, S., Babendure, J. L., Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi, N.-W., & Olefsky, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504611200 · Cited by 411
Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O’Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2013) · Diabetes · doi:10.2337/db12-1139 · Cited by 332 · cited 2×
“Moreover, a significant decrease in fasting blood glucose levels after apigenin consumption was observed in HFD-fed mice [11] and streptozotocin-induced type 1 diabetic rats [21].”
BackgroundLeptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235
Dahlman, I., Forsgren, M., Sjögren, A., Nordström, E. A., Kaaman, M., Näslund, E., Attersand, A., & Arner, P. (2006) · Diabetes · doi:10.2337/db05-1421 · Cited by 184
Cited by
Ginwala, R., Bhavsar, R., Chigbu, D. G. I., Jain, P., & Khan, Z. K. (2019) · Antioxidants · doi:10.3390/antiox8020035 · Cited by 588
Do, M. H., Lee, E., Oh, M.-J., Kim, Y., & Park, H.-Y. (2018) · Nutrients · doi:10.3390/nu10060761 · Cited by 441
Apigenin Enhances Skeletal Muscle Hypertrophy and Myoblast Differentiation by Regulating Prmt7
Jang, Y. J., Son, H. J., Choi, Y. M., Ahn, J., Jung, C. H., & Ha, T. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20962 · Cited by 59
Therapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus
Tamel Selvan, K., Goon, J. A., Makpol, S., & Tan, J. K. (2023) · Marine Drugs · doi:10.3390/md21090462 · Cited by 32
Metadata
- Authors
- Jung, U., Cho, Y.-Y., & Choi, M.-S.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2016-05-19
- Volume
- 8
- Issue
- 5
- Pages
- 305
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2395178553
- Cited by
- 157
- References
- 10
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.